Here's Why Biogen Could Be in Store for a Big 2014 Motley Fool It's been a great year for Biogen (NASDAQ: BIIB ) investors. Shares in the company have more than doubled as sales climbed more than 25% to nearly $7 billion in the past year. A lot of that success is thanks to surging sales for its new oral MS drug ... |
